Global Donepezil Drivers 2025, Forecast To 2034
26 Mar, 2025
How Has the Donepezil Market Size Evolved in Recent Years?
The donepezil market has seen considerable growth due to a variety of factors.
• The market size for donepezil has seen a robust expansion in the past few years. It is projected to ascend from a value of $1.00 billion in 2024 to $1.05 billion in 2025, presenting a compound annual growth rate (CAGR) of 5.1%.
This growth during the historical period is credited to factors such as the escalating incidence of Alzheimer's disease, an enlarging elderly population, an increase in government expenditures and initiatives, heightened awareness of neurodegenerative conditions, and a surge in demand for high-quality nucleic acid samples.
What are the Market Size and Expected Growth Rates for the Donepezil Market?
The donepezil market is expected to maintain its strong growth trajectory in upcoming years.
• In the forthcoming years, the donepezil market is anticipated to witness consistent expansion, reaching $1.27 billion by 2029, with a 4.9% compound annual growth rate (CAGR). The projected growth during the forecast period can be credited to escalating healthcare costs, an intensified attention on the early detection of Alzheimer's disease, an increasing need for combination treatments, substantial investment in healthcare infrastructure, and growing awareness about neurodegenerative diseases. The forecast period will also see notable trends such as advancements in drug formulation and distribution techniques, technological innovation, the introduction of new dosage and formulation types, the sanctioning of donepezil's generic versions, and enhanced research facilities.
Which Key Drivers Are Propelling The Donepezil Market's Growth?
The escalating rates of Alzheimer's disease is projected to fuel the advancement of the Donepezil market in the future. Alzheimer's disease is an advancing neurological condition that results in the degradation and death of brain cells, causing a loss of memory, cognitive deterioration, and behavioral shifts. Numerous reasons, such as an aging populace, population increase, lifestyle associated factors, a surge in chronic disorders, hereditary factors, and environmental exposures, are contributing to an increase in Alzheimer's disease cases. Donepezil functions as a potent symptomatic solution for Alzheimer's disease by improving cognitive capabilities and skills for daily living by influencing acetylcholine levels in the brain. For example, a report by the Alzheimer’s Association, a US-centric nonprofit entity committed to Alzheimer's care, aid, and research, stated in May 2024, that the quantity of Americans aged 65 and above diagnosed with Alzheimer's dementia increased from 6.5 million in 2022 to a projected 6.9 million in 2024. Thus, the surging occurrence of Alzheimer's is promoting the growth of the Donepezil market.
What Are The Key Segments Within The Global Donepezil Market?
The donepezil market covered in this report is segmented –
1) By Type: 5mg, 10mg, 23mg
2) By Route Of Administration: Oral, Transdermal
3) By Application: Hospitals, Clinics, Drugstore
Subsegments:
1) By 5mg: Immediate-Release 5mg, Orally Disintegrating 5mg
2) By 10mg: Immediate-Release 10mg, Orally Disintegrating 10mg
3) By 23mg: Extended-Release 23mg, Film-Coated 23mg
How Are New Trends Impacting The Size Of The Donepezil Market?
Leading companies in the donepezil market are channeling their energies towards the creation of innovative technologies like the donepezil system, with the aim of increasing patient compliance and enhancing treatment efficacy with novel formulations like extended-release. Donepezil functions as a system within the pharmacological setup, mainly focusing on the treatment of Alzheimer's disease and other types of dementia. In a prominent development in October 2022, Corium Innovation Inc., a biopharmaceutical firm based in the US, introduced a donepezil transdermal system (Adlarity) specifically designed to treat Alzheimer disease (AD) dementia ranging from mild to severe. This new transdermal version of donepezil allows the drug to be delivered directly via the skin, effectively bypassing the digestive system. This strategy greatly minimizes the chances of gastrointestinal side effects and provides a more convenient way of administration, which is advantageous for both Alzheimer’s disease patients and their caregivers.
Who Are the Key Players In The Donepezil Market?
Major companies operating in the donepezil market are:
• AbbVie Inc.
• Pfizer Inc.
• Teva Pharmaceutical Inc.
• Intas Pharmaceuticals Ltd.
• Mylan NV
• Sandoz Group AG
• Hetero Drugs Ltd.
• Sun Pharmaceutical Inc.
• Eisai Co. Ltd.
• Cipla Ltd.
• Dr Reddy's Laboratories
• Apotex Inc.
• H Lundbeck A/S
• Zydus Cadila
• Amneal Pharmaceuticals LLC
• Torrent Pharmaceuticals Ltd
• Alkem Laboratories Ltd.
• Jubilant Pharmova Ltd.
• Wockhardt Ltd.
• Luoxin Pharmaceuticals Group
What Are The Regional Insights Into The Donepezil Market?
North America was the largest region in the donepezil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the donepezil market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.